12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lomitapide regulatory update

FDA accepted for review an NDA from Aegerion for lomitapide to treat homozygous familial hypercholesterolemia (HoFH). The PDUFA date is Dec. 29. In March, FDA...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >